Response to commentary: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study - determination of immunogenicity

MeSH terms

• Clinical Trials, Phase III as Topic
• Enzyme Replacement Therapy
• Fabry Disease* / drug therapy
• Fabry Disease* / genetics
• Fabry Disease* / immunology
• Humans
• Isoenzymes* / therapeutic use
• Randomized Controlled Trials as Topic
• Recombinant Proteins* / therapeutic use
• alpha-Galactosidase* / genetics
• alpha-Galactosidase* / immunology
• alpha-Galactosidase* / therapeutic use